Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics, Inc. develops clinical-stage protein kinase inhibitor therapeutics for cardiopulmonary disease, with IKT-001, an oral prodrug of imatinib mesylate, as its lead program for pulmonary arterial hypertension. Company news centers on the IMPROVE-PAH clinical program, FDA interactions, clinical-development milestones, and PAH biology involving Abelson tyrosine kinase, platelet-derived growth factor receptors and c-KIT.
Recurring updates also cover operating results, development spending, equity compensation under Nasdaq rules, common-stock and warrant financing activity, and leadership or commercial-planning changes tied to the PAH program.
Inhibikase Therapeutics (Nasdaq: IKT) reported second quarter 2026 results and progress on its lead PAH candidate IKT-001. The global Phase 3 IMPROVE-PAH trial has regulatory approvals in 26 countries, with 3 additional approvals pending and 4 submissions planned, and 43 clinical sites recently initiated. The adaptive Phase 3 study will enroll about 486 patients across Parts A and B, with primary endpoints of pulmonary vascular resistance and 6-minute walk distance.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $159.0 million. In July 2026, the company raised $50 million via an at-the-market sale of 25,000,000 shares to RA Capital, later exchanging 18,030,000 shares for pre-funded warrants. Net loss for Q2 2026 was $19.6 million ($0.11 per share) versus $9.9 million ($0.11 per share) a year earlier, driven by higher R&D of $13.4 million and SG&A of $7.7 million. The FDA granted Orphan Drug Designation for IKT-001, and the company expects current cash plus warrant proceeds, assuming full and timely exercise, to fund operations through topline Part B data.
Inhibikase Therapeutics (Nasdaq: IKT) announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of Pulmonary Arterial Hypertension (PAH).
According to Inhibikase, ODD applies to the active moiety imatinib and was granted by the FDA's Office of Orphan Products Development. The designation may provide development incentives including eligibility for tax credits on qualified clinical trial costs, exemption from certain FDA user fees, and a potential seven years of U.S. market exclusivity upon regulatory approval.
Inhibikase is running a single pivotal Phase 3 study, IMPROVE-PAH, in PAH across approximately 180 sites worldwide, which is actively enrolling patients. The company highlights pre-clinical data showing improvements in pulmonary vascular and hemodynamic markers of PAH and a lower potential for GI toxicity versus imatinib mesylate.
Inhibikase Therapeutics (Nasdaq: IKT) sold 25,000,000 shares of common stock to RA Capital Management through its at-the-market (ATM) facility, generating $50 million in gross proceeds. According to the company, the additional capital, together with existing cash, is expected to fund operations through topline data readout in Part B of the global Phase 3 IMPROVE-PAH trial, subject to the full exercise of outstanding Series A and B Warrants.
The shares were issued under an effective shelf registration statement on Form S-3 (File No. 333-288213) and an ATM prospectus supplement filed December 19, 2025. The company emphasized that this announcement is not an offer or solicitation to sell securities in any jurisdiction where such actions would be unlawful.
Inhibikase Therapeutics (Nasdaq: IKT) granted non-qualified stock options for up to 981,243 shares to seven newly hired non-executive employees under its 2026 Inducement Equity Plan, effective June 30, 2026. Options have a $2.03 exercise price, ten-year term, and structured four-year vesting schedule.
Inhibikase Therapeutics (Nasdaq: IKT) reported first quarter 2026 results and progress for IKT-001 in pulmonary arterial hypertension.
IMPROVE-PAH, a global two-part Phase 3 trial, has country approvals in 16 nations, first U.S. sites activated, and first patient enrolled. The company held $170.4M in cash and equivalents, with Q1 2026 net loss of $16.4M.
Inhibikase Therapeutics (Nasdaq: IKT) announced the first patient enrollment in IMPROVE-PAH, a global adaptive Phase 3 study of IKT-001 for pulmonary arterial hypertension dated April 7, 2026. The two-part trial includes Part A (~140 patients) with a 24-week PVR endpoint and Part B (~346 patients) with a 24-week 6MWD endpoint.
The protocol permits a 12-week dose-titration, sample-size re-estimation for Part B, up to ~180 global sites, and follows written responses received from the FDA supporting the revised pivotal design.
Inhibikase Therapeutics (Nasdaq: IKT) granted non-qualified stock options for an aggregate of 685,718 shares to five newly hired non-executive employees under its 2026 Inducement Equity Plan, effective March 31, 2026. The options carry a $1.68 exercise price, equal to the closing price on the effective date.
The awards have a 10-year term, with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments. Grants were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
Inhibikase Therapeutics (Nasdaq: IKT) reported full-year 2025 results and operational milestones on March 26, 2026. Key items: initiation of the global pivotal Phase 3 adaptive study IMPROVE-PAH for IKT-001, regulatory submissions in 20+ countries, FAST-EU acceptance, a $115 million public offering, and $178.8M cash at year-end.
2025 net loss was $48.3M versus $27.5M in 2024; R&D rose to $29.8M, including a $7.4M IPR&D write-off tied to the CorHepta acquisition.
Inhibikase Therapeutics (NASDAQ: IKT) priced an underwritten public offering to raise approximately $100.0 million in gross proceeds. The company is offering 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares. Common shares are priced at $1.45 each; pre-funded warrants at $1.449 each (reflecting a $0.001 exercise price). Underwriters have a 30-day option to buy up to 10,344,827 additional shares. The offering is expected to close on November 24, 2025, subject to customary closing conditions.
Jefferies, BofA Securities and Cantor are joint book-running managers; other managers include LifeSci Capital, Oppenheimer, H.C. Wainwright and Ladenburg Thalmann.
Inhibikase Therapeutics (NASDAQ: IKT) on Nov 20, 2025 announced a proposed underwritten public offering of common stock and, for some investors, pre-funded warrants exercisable for common stock. The company also intends to grant underwriters a 30‑day option to purchase up to an additional 15% of the shares at the public offering price, less underwriting discounts and commissions.
The offering is being made from a shelf registration on Form S-3 (No. 333-288213) declared effective June 27, 2025, is subject to market and other conditions, and may not be completed. Jefferies, BofA Securities and Cantor are joint book‑running managers; LifeSci Capital and Oppenheimer are co‑lead managers; H.C. Wainwright and Ladenburg Thalmann are co‑managers. A preliminary prospectus supplement will be filed with the SEC.